Home > Insider Trading > Filing (0000899243-18-017781)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619841	M. Rajeev Shah	C/O Ra Capital Management Llc 20 Park Plaza, Suite 1200 Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-22	1,103,847	$0.00	1,103,847	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-22	1,058,824	$17.00	2,162,671	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-22	922,950	$0.00	1,103,847	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The convertible preferred stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a 1.196-for-one basis, and had no expiration date.
Includes (a) 898,533 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P.(the "Fund") and (b) 205,314 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a member of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.
Includes (a) 856,266 shares of Common Stock held by the Fund and (b) 202,558 held in the Account, in each case acquired in the Issuer's initial public offering.
These securities include 1,754,799 shares held by the Fund and 407,872 shares held in the Account.
Represents 751,282 shares of Series B Convertible Preferred Stock held by the Fund and 171,668 shares of Series B Convertible Preferred Stock held in the Account.